TrialClinical cancer research : an official journal of the American Association for Cancer Research2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.
Max Schlaak et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.